Today, privately-held Chiasma Inc. announced positive results from a late-stage study evaluating its investigational rare endocrine disease drug. The company said that results from the Phase III study of octreotide capsules were published online for early release by the Journal of Clinical Endocrinology & Metabolism (JCEM). The investigational drug, octreotide …